Immune cell populations and T-cell function analysis among trilaciclib responders versus non-responders
To determine if the impact on T-cell effector function was attributable to clinical outcomes, data from responders and non‑responders who were treated with trilaciclib were compared. After two cycles, T-cell numbers were maintained in trilaciclib responders but significantly reduced in non‑responders (Changes to immune cell populations in peripheral blood over two cycles (C1D1 vs. C3D1) for trilaciclib responders and non-responders. Changes to 